Adam Maeder Analyst PerformanceResearch Analyst at Piper SandlerAdam Maeder is a stock analyst at Piper Sandler in the medical sector, covering 14 publicly traded companies. Over the past year, Adam Maeder has issued 32 stock ratings, including buy and hold recommendations. While full access to Adam Maeder's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Adam Maeder's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings62 Last 6 YearsBuy Recommendations71.93% 41 Buy RatingsCompanies Covered14 Unique Companies Ratings Distribution57RatingsDistribution of strong buy, buy, hold, and sell ratings by Adam Maeder.RatingPercentageCount Strong Buy0.0%0 ratings Buy71.9%41 ratings Hold28.1%16 ratings Sell0.0%0 ratingsOut of 57 total stock ratings issued by Adam Maeder at Piper Sandler, the majority (71.9%) have been Buy recommendations, followed by 28.1% Hold.Best & Worst CallsBest Call0000.0%INSPSep 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%TCMDNov 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ50.0% of companies on NASDAQ7 companiesNYSE42.9% of companies on NYSE6 companiesNYSEAMERICAN7.1% of companies on NYSEAMERICAN1 companyAdam Maeder, an analyst at Piper Sandler, currently covers 14 companies listed on NASDAQ, NYSE and NYSEAMERICAN, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical14 companies100.0%Adam Maeder of Piper Sandler specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED INSTRUMENTS8 companies57.1%MEDICAL INFO SYS2 companies14.3%MED PRODUCTS2 companies14.3%MED/DENTAL - SUPP1 company7.1%SURGICAL & MEDICAL INSTRUMENTS1 company7.1% About Adam MaederAdam Maeder is a managing director and senior research analyst focused on the medical technology sector. Prior to joining Piper Sandler in 2019, Maeder worked in medical technology equity research at Wells Fargo Securities. Additionally, he worked at Westwicke Partners providing investor relations strategy and capital markets advisory to medical technology and diagnostics companies. Maeder began his career working on the equity capital markets desk at Piper Sandler. Maeder holds a BBA in finance from the University of Iowa.Follow on LinkedIn Adam Maeder's Ratings History at Piper Sandler Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsSTAASTAAR Surgical5/14/2026Boost Price Target$29.40$33.00Neutral$0.0000.00% ROINYXHNyxoah5/13/2026Reiterated Rating$3.07$7.00Overweight$0.0000.00% ROISTXSStereotaxis5/13/2026Reiterated Rating$1.92$3.50Overweight$0.0000.00% ROINSPRInspireMD5/5/2026Reiterated Rating$1.17$3.00Overweight$0.0000.00% ROIINSPInspire Medical Systems5/5/2026Downgrade$54.77$55.00Neutral$0.0000.00% ROIISRGIntuitive Surgical4/22/2026Lower Price Target$451.29$580.00Overweight$0.0000.00% ROIABTAbbott Laboratories4/17/2026Lower Price Target$95.08$115.00Overweight$0.0000.00% ROIRXSTRxSight2/26/2026Lower Price Target$7.44$10.00Neutral$0.0000.00% ROILIVNLivaNova2/19/2026Reiterated Rating$67.26$85.00Overweight$0.0000.00% ROITCMDTactile Systems Technology2/18/2026Boost Price Target$28.05$42.00Overweight$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. INSPInspire Medical Systems2/12/2026Lower Price Target$68.50$85.00Overweight$0.0000.00% ROIEWEdwards Lifesciences2/11/2026Reiterated Rating$77.00$100.00Overweight$0.0000.00% ROIRMDResMed1/30/2026Boost Price Target$257.83$275.00Neutral$0.0000.00% ROIISRGIntuitive Surgical1/23/2026Reiterated Rating$525.81$620.00Overweight$0.0000.00% ROIABTAbbott Laboratories1/23/2026Lower Price Target$108.50$135.00Overweight$0.0000.00% ROIRXSTRxSight1/20/2026Boost Price Target$9.81$11.00Neutral$0.0000.00% ROIEWEdwards Lifesciences1/20/2026Reiterated Rating$84.39$98.00Overweight$0.0000.00% ROITCMDTactile Systems Technology1/5/2026Set Price Target$27.40$35.00$0.0000.00% ROITCMDTactile Systems Technology1/5/2026Upgrade$27.40$35.00Overweight$0.0000.00% ROISGHTSight Sciences1/5/2026Upgrade$7.48$9.00Overweight$0.0000.00% ROIINSPInspire Medical Systems12/8/2025Boost Price Target$136.75$165.00Overweight$0.0000.00% ROINYXHNyxoah11/14/2025Reiterated Rating$5.31$9.00Overweight$0.0000.00% ROISGHTSight Sciences11/7/2025Boost Price Target$5.00$5.00Neutral$0.0000.00% ROITCMDTactile Systems Technology11/4/2025Reiterated Rating$21.77$20.00Neutral$0.0000.00% ROIINSPInspire Medical Systems11/4/2025Reiterated Rating$85.03$135.00Overweight$0.0000.00% ROIEWEdwards Lifesciences10/31/2025Reiterated Rating$84.09$95.00Overweight$0.0000.00% ROIISRGIntuitive Surgical10/22/2025Boost Price Target$462.74$610.00Overweight$0.0000.00% ROIRBOTVicarious Surgical8/13/2025Lower Price Target$9.25$7.00Neutral$0.0000.00% ROIINSPInspire Medical Systems8/5/2025Lower Price Target$130.79$150.00Overweight$0.0000.00% ROIRMDResMed8/1/2025Boost Price Target$272.16$270.00Neutral$0.0000.00% ROIEWEdwards Lifesciences7/25/2025Boost Price Target$79.41$90.00Overweight$0.0000.00% ROIISRGIntuitive Surgical7/23/2025Reiterated Rating$496.23$595.00Overweight$0.0000.00% ROINSPRInspireMD5/12/2025Lower Price Target$2.54$4.00Overweight$0.0000.00% ROITCMDTactile Systems Technology5/6/2025Downgrade$13.94$14.00Neutral$00.0000.00% ROIEWEdwards Lifesciences4/24/2025Upgrade$70.33$80.00Overweight$00.0000.00% ROIISRGIntuitive Surgical4/23/2025Lower Price Target$492.31$575.00Overweight$000.0000.00% ROIABTAbbott Laboratories4/17/2025Reiterated Rating$131.84$145.00Overweight$00.0000.00% ROIRXSTRxSight4/15/2025Initiated Coverage$14.42$18.00Neutral$0.0000.00% ROIRBOTVicarious Surgical3/18/2025Lower Price Target$9.10$8.50Neutral$0.0000.00% ROIEWEdwards Lifesciences2/12/2025Boost Price Target$75.47$73.00Neutral$00.0000.00% ROIBefore you buy SpaceX shares, consider this alternative approach (Ad)SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.Discover the overlooked SpaceX IPO strategy before the June listingINSPInspire Medical Systems2/10/2025Lower Price Target$182.00$233.00Overweight$00.0000.00% ROIISRGIntuitive Surgical1/24/2025Reiterated Rating$587.08$670.00Overweight$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenWeiss RatingsUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
